ClinicalTrials.gg
CompletedNCT07735052Updated Jul 29, 2026

Drug-drug Interaction Study Between UIC202304, and UIC202305

A Phase 1 interventional study of UIC202304 and co-administration of UIC202304 and UIC202305 and UIC202305 and co-administration of UIC202304 and UIC202305 in Healhty, sponsored by Korea United Pharm. Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Korea United Pharm. Inc. · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Sep 2023, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

A randomized, open-label, two-sequence, two-period, multiple-dose, study to evaluate pharmacokinetic drug-drug interaction, safety and tolerability of UIC202304 and UIC202305 in healthy volunteers.

02

Conditions studied

  • Healhty
03

In context

Lead sponsor

Korea United Pharm. Inc. is the lead sponsor of 22 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult volunteers aged 19 years or older and younger than 55 years at the time of screening.
  2. Male participants weighing at least 50 kg and female participants weighing at least 45 kg, with a , BMI, between 18.0 and 30.0 kg/m², inclusive.
  3. Participants with no congenital or chronic diseases and no pathological symptoms or findings based on medical examination.
  4. Participants who are judged by the investigator to be eligible for the study based on medical history, physical examination, clinical laboratory tests, and 12-lead , ECG, performed within 4 weeks prior to the first administration of the product, considering the characteristics of the investigational product.
  5. Participants who are able to understand and comply with the study instructions and who are available to participate for the entire duration of the clinical trial.
  6. Participants who agree to use during the clinical trial and are able to comply with medically acceptable contraceptive methods, including a medically sterile or non-fertile condition. See Section 9.3.1 for acceptable contraceptive methods.
  7. Participants who voluntarily decide to participate in the clinical trial after receiving and fully understanding a detailed explanation of the study and who provide written to comply with study requirements and precautions.

Exclusion criteria

Exclusion Criteria:

1. Medical History

  1. Participants with a current or past history of diseases involving the biliary system, including biliary obstructive disease; renal system, including severe renal impairment; hematologic or oncologic disorders; cardiovascular system, including congestive heart failure, coronary artery disease, aortic or mitral valve stenosis or related complications, arrhythmia, or renovascular hypertension; respiratory system, including asthma or ; liver disease, including moderate or severe hepatic impairment; endocrine system, including diabetes mellitus, impaired glucose tolerance, hypothyroidism, or primary aldosteronism; gastrointestinal system; musculoskeletal system; central nervous system, including Parkinson's disease; psychiatric disorders; or malignant tumors.
  2. Participants who are vulnerable to dehydration due to inadequate oral intake or who show clinically significant signs of dehydration.
  3. Participants with a current or past history of gastrointestinal diseases that may affect drug absorption, including Crohn's disease, ulcer, gastritis, gastric spasm, gastroesophageal reflux disease, acute or chronic pancreatitis, or gastrointestinal surgery, except simple appendectomy or hernia repair.
  4. Participants with hereditary angioedema or a history of angioedema during treatment with angiotensin-converting enzyme, ACE, inhibitors or angiotensin II receptor blockers.
  5. Participants with a history of or clinically significant hypersensitivity to amlodipine, telmisartan, atorvastatin, ezetimibe, drugs of similar classes, including other dihydropyridines, or other drugs, including aspirin or antibiotics.
  6. Participants who have had a clinically significant disease within 30 days prior to the first administration of the product.

2. Clinical Laboratory Tests and Examinations

  1. Participants who, after sufficient rest, show any of the following vital sign values measured in a sitting position: systolic blood pressure >140 mmHg or \<100 mmHg, diastolic blood pressure >90 mmHg or \<60 mmHg, or pulse rate >100 beats/min or \<60 beats/min.
  2. Participants with positive results for serologic tests, including , , syphilis, or , HIV.
  3. Participants with serum , ALT, or total levels greater than 1.5 times the , ULN.
  4. Participants with , GFR, calculated using the formula, of \<60 mL/min.
  5. Participants with creatine phosphokinase, CPK, levels increased to 5 times or more the upper limit of normal, ULN.
  6. Participants with clinically significant findings on 12-lead , ECG, or associated physical abnormalities or symptoms.
  7. Participants who are judged by the investigator to be unsuitable for study participation based on physical examination or other findings.

3. Allergy and Drug Abuse

  1. Participants with genetic problems such as intolerance to the investigational product.
  2. Participants with a history of drug abuse or a positive result for drugs of abuse in a drug screening test.
  3. Participants with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

4. Prohibited Concomitant Medications and Diet

  1. Participants who have participated in another clinical trial within 180 days prior to the first administration of the investigational product.
  2. Participants who have taken drugs that induce or inhibit drug metabolism, including inducers or inhibitors, or drugs that inhibit drug transporters, including glecaprevir and pibrentasvir, within 28 days prior to the first administration of the investigational product.
  3. Participants who have taken herbal medicines within 28 days, prescription drugs within 14 days, or over-the-counter drugs within 7 days prior to the first administration of the investigational product. However, participants may be allowed to participate in the clinical trial if the investigator determines that other conditions are appropriate.
  4. Participants who have consumed grapefruit or grapefruit-containing foods within 7 days prior to the first administration of the investigational product, or who are unable to refrain from consuming them during the study period.

5. Other Criteria

  1. Participants who have donated whole blood within 60 days, donated blood components within 28 days, or received a blood transfusion within 28 days prior to the first administration of the investigational product.
  2. Participants who have consumed excessive alcohol within 28 days prior to the first administration of the investigational product, defined as alcohol >30 g/day; soju >150 mL/day, based on 20% alcohol content; beer >750 mL/day, based on 4% alcohol content; liquor >75 mL/day, based on 40% alcohol content; or wine >300 mL/day, based on 10% alcohol content.
  3. Participants who have smoked excessively within 28 days prior to the first administration of the investigational product, defined as >10 cigarettes/day, or who are unable to stop smoking during the clinical trial.
  4. Participants who have consumed excessive caffeine within 28 days prior to the first administration of the investigational product, defined as coffee >5 cups/day, tea >1,250 mL/day, or cola >1,250 mL/day.
  5. Participants who continuously consume alcohol or are unable to abstain from alcohol during the clinical trial.
  6. Female participants who are pregnant or breastfeeding.
  7. Participants who are judged by the investigator or study physician to be unsuitable for participation in the clinical trial for any other reason, including clinical laboratory test results, withdrawal of consent prior to admission for Period 1, or excessive tattoos.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    UIC202304 followed by coadministration With UIC202305

    UIC202304 and co-administration of UIC202304 and UIC202305

    Drug: UIC202304 and co-administration of UIC202304 and UIC202305

  • Experimental
    UIC202305 followed by coadministration With UIC202304

    UIC202305 and co-administration of UIC202304 and UIC202305

    Drug: UIC202305 and co-administration of UIC202304 and UIC202305

Interventions

  • DrugUIC202304 and co-administration of UIC202304 and UIC202305

    * UIC202304 1 Tab/day for 9 days * UIC202304 1 Tab/day + UIC202305 1 Tab/day for 7 days

  • DrugUIC202305 and co-administration of UIC202304 and UIC202305

    * UIC202305 1 Tab/day for 7 days * UIC202304 1 Tab/day + UIC202305 1 Tab/day for 9 days

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady State (AUCss,τ)

    AUCss,τ will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

  2. Maximum Plasma Concentration at Steady State (Css,max)

    Css,max will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity at Steady State (AUCss,inf)

    Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity at Steady State (AUCss,inf) will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

  2. Time to Maximum Plasma Concentration at Steady State (Tss,max)

    Time to Maximum Plasma Concentration at Steady State (Tss,max) will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

  3. Elimination Half-Life at Steady State (tss,1/2)

    Elimination Half-Life at Steady State (tss,1/2) will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

  4. Minimum Plasma Concentration at Steady State (Css,min)

    Minimum Plasma Concentration at Steady State (Css,min) will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

  5. Apparent Total Body Clearance at Steady State (CLss/F)

    Apparent Total Body Clearance at Steady State (CLss/F) will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

  6. Apparent Volume of Distribution (Vd/F)

    Apparent Volume of Distribution (Vd/F) will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

  7. Peak-to-Trough Fluctuation at Steady State (PTF)

    Peak-to-Trough Fluctuation at Steady State (PTF) will be determined for amlodipine, telmisartan, atorvastatin, 2-hydroxy atorvastatin, total ezetimibe, and free ezetimibe.

    Time frame: Predose (0 hour) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 9 and 16 for UIC202304 alone and with UIC202305, and on Days 7 and 16 for UIC202305 alone and with UIC202304.

07

Study locations

1 site
  • Metro Hospital
    Anyang-si, Gyeonggi-do 14086, South Korea
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Nov 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 29, 2026
StartActual
Sep 25, 2023
Primary completionActual
Nov 24, 2023
CompletionActual
Sep 9, 2024
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07735052
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 25, 2023
Primary completion
Nov 24, 2023
Completion
Sep 9, 2024
Last update
Jul 29, 2026

Study contacts

Sung-Dae Kwon, M.D.,Ph.D
principal investigator · Metro Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion